相似文献
1
Myocarditis after COVID-19 mRNA vaccination: clinical observations and potential mechanisms.
Nat Rev Cardiol. 2022 Feb;19(2):75-77. doi: 10.1038/s41569-021-00662-w.
2
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US.
JAMA. 2022 May 24;327(20):2019-2020. doi: 10.1001/jama.2022.5131.
3
Myocarditis Cases After mRNA-Based COVID-19 Vaccination in the US-Reply.
JAMA. 2022 May 24;327(20):2020-2021. doi: 10.1001/jama.2022.5134.
4
Features of Inflammatory Heart Reactions Following mRNA COVID-19 Vaccination at a Global Level.
Clin Pharmacol Ther. 2022 Mar;111(3):605-613. doi: 10.1002/cpt.2499. Epub 2021 Dec 27.
5
Meta-Analysis of Risk of Myocarditis After Messenger RNA COVID-19 Vaccine.
Am J Cardiol. 2022 Mar 15;167:155-157. doi: 10.1016/j.amjcard.2021.12.007. Epub 2022 Jan 19.
6
Use of mRNA COVID-19 Vaccine After Reports of Myocarditis Among Vaccine Recipients: Update from the Advisory Committee on Immunization Practices - United States, June 2021.
MMWR Morb Mortal Wkly Rep. 2021 Jul 9;70(27):977-982. doi: 10.15585/mmwr.mm7027e2.
7
Incidence, risk factors, natural history, and hypothesised mechanisms of myocarditis and pericarditis following covid-19 vaccination: living evidence syntheses and review.
BMJ. 2022 Jul 13;378:e069445. doi: 10.1136/bmj-2021-069445.
8
Two Cases of Acute Myocarditis in Young Male Adults After mRNA Vaccines Against COVID-19: Similarities and Differences.
Med Arch. 2022 Jun;76(3):215-220. doi: 10.5455/medarh.2022.76.215-220.
9
Definite Acute Myocarditis After Coronavirus Disease 2019 mRNA Vaccination.
Circ J. 2022 Mar 25;86(4):724. doi: 10.1253/circj.CJ-21-0840. Epub 2021 Dec 4.
10
Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma.
BMC Cancer. 2021 Dec 27;21(1):1354. doi: 10.1186/s12885-021-09097-5.
引用本文的文献
1
Rural-Urban Disparities in COVID-19 Vaccine Uptake and Associated Mortality and Cardiovascular Disease Outcomes in the United States.
Vaccines (Basel). 2025 Aug 14;13(8):861. doi: 10.3390/vaccines13080861.
2
The early impact of COVID-19 vaccines on major events in cardiac, pulmonary, and thromboembolic disease: a population-based study.
Korean J Intern Med. 2025 Sep;40(5):801-812. doi: 10.3904/kjim.2025.056. Epub 2025 Aug 26.
3
Myocarditis Following COVID-19 Vaccine: What Did We Learn?
Sage Open Pediatr. 2025 Jun 20;12:30502225251336877. doi: 10.1177/30502225251336877. eCollection 2025 Jan-Dec.
4
Cardiopulmonary Effects of COVID-19 Vaccination: A Comprehensive Narrative Review.
Vaccines (Basel). 2025 May 22;13(6):548. doi: 10.3390/vaccines13060548.
5
The New Era of mRNA Vaccines: The Success of the COVID-19 Vaccines and the Safety Concerns in Adolescents.
Indian J Community Med. 2025 May-Jun;50(3):404-406. doi: 10.4103/ijcm.ijcm_544_23. Epub 2024 Nov 13.
6
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.
Vaccines (Basel). 2025 Apr 28;13(5):473. doi: 10.3390/vaccines13050473.
7
COVID-19 and Diabetes: Persistent Cardiovascular and Renal Risks in the Post-Pandemic Landscape.
Life (Basel). 2025 Apr 30;15(5):726. doi: 10.3390/life15050726.
8
Global, regional, and national burden of myocarditis and its attributable risk factors in 204 countries and territories from 1990 to 2021: updated systematic analysis.
Front Public Health. 2025 Apr 28;13:1542921. doi: 10.3389/fpubh.2025.1542921. eCollection 2025.
9
The COVID-19 pandemic in children and young people during 2022-24: what new did we learn?
J Glob Health. 2025 Apr 2;15:01002. doi: 10.7189/jogh.15.01002.
10
A case report of severe myocarditis combined with erythema multiforme caused by herpes simplex virus-1.
Front Cardiovasc Med. 2025 Mar 12;12:1421364. doi: 10.3389/fcvm.2025.1421364. eCollection 2025.
本文引用的文献
1
Myocarditis after Covid-19 Vaccination in a Large Health Care Organization.
N Engl J Med. 2021 Dec 2;385(23):2132-2139. doi: 10.1056/NEJMoa2110737. Epub 2021 Oct 6.
2
Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel.
N Engl J Med. 2021 Dec 2;385(23):2140-2149. doi: 10.1056/NEJMoa2109730. Epub 2021 Oct 6.
3
Myocardial Pathology in COVID-19-Associated Cardiac Injury: A Systematic Review.
Diagnostics (Basel). 2021 Sep 8;11(9):1647. doi: 10.3390/diagnostics11091647.
4
Surveillance for Adverse Events After COVID-19 mRNA Vaccination.
JAMA. 2021 Oct 12;326(14):1390-1399. doi: 10.1001/jama.2021.15072.
5
Myocarditis Following Immunization With mRNA COVID-19 Vaccines in Members of the US Military.
JAMA Cardiol. 2021 Oct 1;6(10):1202-1206. doi: 10.1001/jamacardio.2021.2833.
6
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
7
Predictors of Mortality in Patients With Biopsy-Proven Viral Myocarditis: 10-Year Outcome Data.
J Am Heart Assoc. 2020 Aug 18;9(16):e015351. doi: 10.1161/JAHA.119.015351. Epub 2020 Aug 13.
8
Myocardial injury characterized by elevated cardiac troponin and in-hospital mortality of COVID-19: An insight from a meta-analysis.
J Med Virol. 2021 Jan;93(1):51-55. doi: 10.1002/jmv.26108. Epub 2020 Jun 19.
9
Potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases.
Clin Immunol. 2020 Aug;217:108480. doi: 10.1016/j.clim.2020.108480. Epub 2020 May 24.
10
The Quest for New Approaches in Myocarditis and Inflammatory Cardiomyopathy.
J Am Coll Cardiol. 2016 Nov 29;68(21):2348-2364. doi: 10.1016/j.jacc.2016.09.937.
Zotero 插件